NextCure
NXTC
71 hedge funds and large institutions have $86.2M invested in NextCure in 2021 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 19 increasing their positions, 23 reducing their positions, and 14 closing their positions.
99% more call options, than puts
Call options by funds: $507K | Put options by funds: $255K
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
0% more funds holding
Funds holding: 71 → 71 (0)
0.11% less ownership
Funds ownership: 4.45% → 4.34% (-0.11%)
13% less capital invested
Capital invested by funds: $99.5M → $86.2M (-$13.3M)
17% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 23
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$5.27M |
| 2 |
Millennium Management
New York
|
+$2.94M |
| 3 |
Goldman Sachs
New York
|
+$1.63M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.51M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$962K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$3.68M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.62M |
| 3 |
CPX
Canaan Partners X
Menlo Park,
California
|
-$2.17M |
| 4 |
LPC
Lion Point Capital
New York
|
-$2.02M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$2.02M |
NXTC Hedge Fund Activity: Q4 2021 in Review
71 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q4 2021, worth a combined $86.2M — down 13% from $99.5M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new NXTC positions and 14 closed out — a net gain of 1 holder — while 19 added to existing stakes and 23 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $5.27M. The largest seller was Silverarc Capital Management, cutting an estimated $3.68M.
- 71 institutional investors held NextCure (NXTC) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $86.2M of NextCure stock for Q4 2021, down 13% quarter-over-quarter.
- 15 funds opened new NextCure positions in Q4 2021 and 14 closed out, a net change of +1 holder.
- The largest NextCure buyer in Q4 2021 was Woodline Partners, an estimated $5.27M added.
- The largest NextCure seller in Q4 2021 was Silverarc Capital Management, an estimated $3.68M sold.
Based on aggregated 13F filings for Q4 2021.